CRISPR Therap N
CRSP
USD
STOCK MARKET:
NMS
Open
 
...
Large gap with delayed quotes
Last quote
04/27/2026 - 19:14:43
Bid
04/27/2026 - 19:15:01
Bid
Volume 		Ask
04/27/2026 - 19:15:01
Ask
Volume
51.50
+2.715 ( +5.57% )
51.49
400
51.65
100
More information
Analysis by TheScreener
24.04.2026
Evaluation Negativ  
Interest None  
Sensibility High  
Analysis date: 24.04.2026
Global Evaluation
  Negativ
The stock is classified in the negative zone since 24.04.2026.
Interest
  None
No stars since 24.04.2026.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 14.04.2026 at a price of 56.86.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Negative
 
The dividend-adjusted forty day technical trend is negative since 24.04.2026.
4wk Rel Perf
  -4.21%
 
The four-week dividend-adjusted underperformance versus SP500 is 4.21%.
Sensibility
  High
High, no change over 1 year.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 1.21%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 4.52%.
Mkt Cap in $bn
  4.70
With a market capitalization between $2 & $8bn, CRISPR THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  0.56
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
  -12.47
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  7.04%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  24
Over the last seven weeks, an average of 24 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  174
For 1% of index variation, the stock varies on average by 1.74%.
Correlation
  0.38
Stock movements are strongly independent of index variations.
Value at Risk
  19.24
The value at risk is estimated at USD 19.24. The risk is therefore 39.45%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  08.09.2020